Active surveillance, upgrading on repeat biopsy, and consequent management

In February this year we commented on an article that argued in favor of active surveillance as an appropriate initial management strategy for “favorable” intermediate-risk prostate cancer. … READ MORE …

Other items from the annual meeting of the AUA

A combination of travel and other commitments made it difficult for your sitemaster to complete his summaries of significant information presented at this year’s annual meeting of the American Urological Association (AUA), so here’s the final wrap-up. … READ MORE …

Active surveillance today: a summary of the Sunnybrook experience and related factors

In an important new paper in Current Opinion in Urology (available free as a full-text article), Dr. Laurie Klotz has provided an excellent summary of his perspective on the current application of active surveillance in the management of low-risk prostate cancer, based on the 20-year experience of the Sunnybrook group and other data. … READ MORE …

Active surveillance is absolutely NOT appropriate for all men with intermediate-risk prostate cancer

A paper to be presented this Thursday at the upcoming Genitourinary Cancers Symposium in  Orlando, Florida, will clearly confirm the above heading, which should come as no surprise to anyone. The issue has always been whether there is a subset of men with (“favorable”) intermediate-risk disease who are potentially appropriate candidates. … READ MORE …

In 2004-07 most Medicare-eligible men were getting radiation therapy for first-line treatment of prostate cancer

In a second article in the new journal JAMA Oncology, researchers at the University of California Los Angeles suggest that 58 percent of all relatively recent treatment for prostate cancer was being given by radiation therapy of some type, and that indolent prostate cancer was being significantly over-treated. … READ MORE …

First and second biopsies and their diagnostic accuracy

A paper by Wong et al. published in December carries the title, “Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer.” … READ MORE …

Published data on Klotz’s active surveillance series at c. 20 years

In a report published on line on Monday, in the Journal of Clinical Oncology, Klotz et al. have now provided peer-reviewed data from their nearly 20-year-long series of patients managed on active surveillance. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,343 other followers